JP2022548095A5 - - Google Patents
Info
- Publication number
- JP2022548095A5 JP2022548095A5 JP2022516379A JP2022516379A JP2022548095A5 JP 2022548095 A5 JP2022548095 A5 JP 2022548095A5 JP 2022516379 A JP2022516379 A JP 2022516379A JP 2022516379 A JP2022516379 A JP 2022516379A JP 2022548095 A5 JP2022548095 A5 JP 2022548095A5
- Authority
- JP
- Japan
- Prior art keywords
- carbocyryl
- heteroatoms selected
- alkyl
- membered
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962901229P | 2019-09-16 | 2019-09-16 | |
| US62/901,229 | 2019-09-16 | ||
| PCT/IB2020/058641 WO2021053555A1 (en) | 2019-09-16 | 2020-09-16 | Glue degraders and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026067413A Division JP2026133390A (ja) | 2019-09-16 | 2026-04-15 | 接着分解剤及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022548095A JP2022548095A (ja) | 2022-11-16 |
| JP2022548095A5 true JP2022548095A5 (cg-RX-API-DMAC7.html) | 2023-09-21 |
| JP7874541B2 JP7874541B2 (ja) | 2026-06-16 |
Family
ID=72717893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022516379A Active JP7874541B2 (ja) | 2019-09-16 | 2020-09-16 | 接着分解剤及びその使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220363671A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4031243A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7874541B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN114401960B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021053555A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES |
| US12454520B2 (en) | 2018-07-06 | 2025-10-28 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| AU2019389174A1 (en) | 2018-11-30 | 2021-07-01 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| PH12022500002A1 (en) | 2019-06-28 | 2023-04-03 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| US12558427B2 (en) | 2019-07-17 | 2026-02-24 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| WO2021119159A1 (en) | 2019-12-10 | 2021-06-17 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| CA3161878A1 (en) | 2019-12-17 | 2021-06-24 | Matthew M. Weiss | Irak degraders and uses thereof |
| EP4076524A4 (en) | 2019-12-17 | 2023-11-29 | Kymera Therapeutics, Inc. | IRAQ DEGRADERS AND USES THEREOF |
| EP4161521A4 (en) | 2020-06-03 | 2024-07-10 | Kymera Therapeutics, Inc. | DEUTERED IRAQ DEGRADERS AND USES THEREOF |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| EP4259128A4 (en) * | 2020-12-09 | 2025-04-30 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| AR124547A1 (es) | 2020-12-30 | 2023-04-05 | Kymera Therapeutics Inc | Degradadores de irak y sus usos |
| CN117242060B (zh) | 2021-01-13 | 2026-07-17 | 蒙特罗莎治疗股份有限公司 | 异吲哚啉酮化合物 |
| WO2022153220A1 (en) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Methods for the identification of degrons |
| WO2022174268A1 (en) | 2021-02-15 | 2022-08-18 | Kymera Therapeutics, Inc. | Irak4 degraders and uses thereof |
| WO2022254362A1 (en) | 2021-06-03 | 2022-12-08 | Novartis Ag | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and medical uses thereof |
| US20240287573A1 (en) | 2021-06-04 | 2024-08-29 | Monte Rosa Therapeutics, Inc. | E3 ligase fusion proteins for proximity detection |
| JP2024540080A (ja) | 2021-10-29 | 2024-10-31 | カイメラ セラピューティクス, インコーポレイテッド | Irak4分解剤およびその合成 |
| WO2023091567A1 (en) | 2021-11-17 | 2023-05-25 | Monte Rosa Therapeutics, Inc. | Degron and neosubstrate identification |
| CN114487379A (zh) * | 2022-01-17 | 2022-05-13 | 东南大学 | 一种用于联合检测ca125与he4的试纸条 |
| EP4472967A4 (en) | 2022-01-31 | 2026-04-15 | Kymera Therapeutics Inc | Iraqi Degradation Agents and Their Uses |
| CN114410607A (zh) * | 2022-03-22 | 2022-04-29 | 上海威高医疗技术发展有限公司 | 嗜热羧酸酯酶突变体及其应用 |
| CN116789637B (zh) * | 2022-05-13 | 2024-08-02 | 上海湃隆生物科技有限公司 | 驱动蛋白kif18a抑制剂及其应用 |
| WO2024073871A1 (en) * | 2022-10-04 | 2024-04-11 | Biofront Ltd | Gspt1 degraders, compositions comprising the degrader, and methods of using the same |
| KR20250135228A (ko) | 2023-01-09 | 2025-09-12 | 몬테 로사 테라퓨틱스 아게 | Vav1의 표적 분해 |
| PE20260307A1 (es) | 2023-06-14 | 2026-02-11 | Astrazeneca Ab | Degradadores de smarca2 y usos de estos |
| IL325247A (en) | 2023-06-14 | 2026-02-01 | Astrazeneca Ab | History of 3-[3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl]-8,3-diazabicyclo[3.2.1]octane as a protacs from SMARCA2 joints for cancer treatment |
| WO2024255810A1 (en) * | 2023-06-15 | 2024-12-19 | Hangzhou Glubio Pharmaceutical Co., Ltd | Dihydropyrimidine-2, 4 (1h, 3h) -dione-containing polycyclic derivatives and pharmaceutical composition thereof, preparation method thereof and use thereof |
| KR20260041885A (ko) | 2023-07-25 | 2026-03-27 | 몬테 로사 테라퓨틱스 아게 | 표적화된 단백질 분해를 위한 치환된 피페리딘디온 |
| WO2025232888A1 (en) * | 2024-05-10 | 2025-11-13 | Shanghai Degron Biomedical Technology Co., Ltd. | Wee1 degraders and uses thereof |
| WO2026013577A1 (en) * | 2024-07-10 | 2026-01-15 | Monte Rosa Therapeutics Ag | Piperidine-2, 6-dione derivatives useful for the targeted degradation of vav1 |
| WO2026013576A1 (en) * | 2024-07-10 | 2026-01-15 | Monte Rosa Therapeutics Ag | Dihydrouracil derivatives useful for the targeted degradation of vav1 |
| WO2026013578A1 (en) * | 2024-07-10 | 2026-01-15 | Monte Rosa Therapeutics Ag | Combinations comprising vav1-targeting degraders |
| WO2026067646A1 (zh) * | 2024-09-27 | 2026-04-02 | 上海美悦生物科技发展有限公司 | 联苯类化合物、及其药物组合物和用途 |
| WO2026108986A1 (zh) * | 2024-11-22 | 2026-05-28 | 上海美悦生物科技发展有限公司 | 杂环烯基类化合物、及其药物组合物和用途 |
| WO2026120044A1 (en) | 2024-12-04 | 2026-06-11 | Astrazeneca Ab | Smarca2 degraders and uses thereof |
| WO2026136866A1 (en) | 2024-12-20 | 2026-06-25 | Prelude Therapeutics Incorporated | Kat6 targeting compounds |
| WO2026154063A1 (en) | 2025-01-16 | 2026-07-23 | Monte Rosa Therapeutics Ag | Reverse turboid |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5114946A (en) | 1987-06-12 | 1992-05-19 | American Cyanamid Company | Transdermal delivery of pharmaceuticals |
| US4818541A (en) | 1987-08-19 | 1989-04-04 | Schering Corporation | Transdermal delivery of enantiomers of phenylpropanolamine |
| TWI428332B (zh) * | 2009-06-09 | 2014-03-01 | Hoffmann La Roche | 雜環抗病毒化合物 |
| CN109153644B (zh) * | 2016-03-16 | 2022-10-21 | H·李·莫菲特癌症中心研究有限公司 | 用以增强效应t细胞功能的针对cereblon的小分子 |
| IL319363A (en) | 2017-01-31 | 2025-05-01 | Arvinas Operations Inc | Cervalon ligands and bifunctional compounds containing them |
| US11512080B2 (en) | 2018-01-12 | 2022-11-29 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| EP3897631A4 (en) * | 2018-12-20 | 2022-11-23 | C4 Therapeutics, Inc. | TARGETED PROTEIN BREAKDOWN |
-
2020
- 2020-09-16 JP JP2022516379A patent/JP7874541B2/ja active Active
- 2020-09-16 CN CN202080063698.5A patent/CN114401960B/zh active Active
- 2020-09-16 CN CN202610566446.3A patent/CN122520640A/zh active Pending
- 2020-09-16 WO PCT/IB2020/058641 patent/WO2021053555A1/en not_active Ceased
- 2020-09-16 US US17/642,292 patent/US20220363671A1/en active Pending
- 2020-09-16 EP EP20785841.6A patent/EP4031243A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI765448B (zh) | Kras g12c抑制劑 | |
| JP2025508703A5 (cg-RX-API-DMAC7.html) | ||
| JP6863970B2 (ja) | ヘテロ環式化合物およびそれらの使用 | |
| JP2024534187A5 (cg-RX-API-DMAC7.html) | ||
| KR102566924B1 (ko) | 케모카인 수용체 조절제 및 이의 용도 | |
| JP2022505835A5 (cg-RX-API-DMAC7.html) | ||
| US20190345138A1 (en) | Heterocyclic amides as kinase inhibitors | |
| CN112154142A (zh) | 整合应激通路的调节剂 | |
| JP2021501788A (ja) | 統合的ストレス経路の調節剤 | |
| JP2021501790A (ja) | 統合的ストレス経路の調節剤 | |
| KR102345381B1 (ko) | 키나제 억제제로서 유용한 카르바졸 카르복스아미드 화합물 | |
| JP2021501787A (ja) | 統合的ストレス経路の調節剤 | |
| JP2015531773A (ja) | スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用 | |
| DK3013814T3 (en) | SUBSTITUTED TETRAHYDROCARBAZOL AND CARBAZOLCARBOXAMIDE COMPOUNDS WHICH CAN BE USED AS KINase INHIBITORS | |
| JP2021501781A (ja) | 統合的ストレス経路の調節剤 | |
| JP2008523041A5 (cg-RX-API-DMAC7.html) | ||
| AU2011268906A1 (en) | Heteroaryl compounds and compositions as protein kinase inhibitors | |
| JP2007534687A5 (cg-RX-API-DMAC7.html) | ||
| MX2010001677A (es) | Derivados de 4-(9-(3,3-difluorociclopentil)-5,7,7-trimetil-6-oxo-6 ,7,8,9-tetrahidro-5h-pirimido[4,5-b][1,4]diazepin-2-ilamino)-3-me toxibenzamida como inhibidores de las proteinas cinasas humanas plk1 a plk4 para el tratamiento de enfermedades proli | |
| RU2007108861A (ru) | Трифтометилзамещенные бензамиды в качестве ингибиторов киназ | |
| EA010393B1 (ru) | Производные хинолинона | |
| JP2005509038A5 (cg-RX-API-DMAC7.html) | ||
| KR102598246B1 (ko) | Jak 저해제로서 헤테로사이클릭 화합물, 및 이의 염 및 치료학적 용도 | |
| JP2013540114A5 (cg-RX-API-DMAC7.html) | ||
| TW201733580A (zh) | Trk抑制劑抵抗性的癌治療劑 |